Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth
-
Duos Edge AI Partners with Accu-Tech To Deploy Edge Data Centers
-
NMI Holdings, Inc. Announces S&P Rating Upgrades
-
Golden Matrix Group to Showcase Expanded Portfolio and Proprietary Technology at G2E Las Vegas 2024
-
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
-
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
-
Wearable Devices Ltd. Announces 1-for-20 Reverse Stock Split
-
PodcastOne (PODC) Appoints Jim Lally Head of Business Development
-
VisiConsult and Glimpse Partner to Launch a High-Resolution, Seconds-Long Full-Cell Scanning Capability for the Battery Industry
-
AFC Gamma Provides Story of Maryland with $41 Million Senior Secured Credit Facility
-
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
-
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
-
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Kratos and Radisys Partner on Cloud Native 5G-NTN OpenSpace® Solutions to Enable Seamless Satellite Access for Terrestrial Networks
-
Bazaarvoice Announces Industry’s First Integrated Social Content Solution, Bazaarvoice Vibe
-
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
-
NIP Group Announces Appointment of New Independent Director
-
Magnite to Announce Third Quarter 2024 Financial Results on November 7, 2024
-
Heliene Partners With Transition Equity Partners to Expand Domestic Solar Manufacturing Capacity
-
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
-
Gabelli Funds to Host 48th Annual Automotive Symposium at The Encore at Wynn, Las Vegas, Nevada
-
Inspire Medical Systems, Inc. to Report Third Quarter 2024 Financial Results on November 4, 2024
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
-
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
-
Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
-
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
-
Taco John’s Taps Kevin Flaherty as its Chief Marketing Officer
-
Form 8.3 - Learning Technologies Group plc - Octopus Investments
-
Landsbankinn hf.: Offering of covered bonds
-
Scandinavian Tobacco Group A/S: CORRECT - Transactions in connection with share buy-back programme
-
Trailbreaker Defines Chargeability Feature Coincident With Multi-Element Geochemical Anomaly at Swan Zone, Atsutla Project, British Columbia
-
The Canadian Vaping Association Responds to Tobacco Control Lobbyists: Banning Flavours in Vaping Products will Harm Public Health and Put Youth at More Risk
-
FTI Consulting Strengthens Global Insurance Services Practice with Senior Hire
-
Western Investment Company Announces Rights Offering
-
Global Crossing Airlines Appoints Laurie Villa as Chief People Officer
-
Garrett Motion to Hold Third Quarter 2024 Financial Results Conference Call on Thursday October 24, 2024
-
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
-
MariMed Announces Third Quarter 2024 Earnings Date
-
Highwire Taps Katherine Zackel to Lead Crisis
-
SemiCab Wins Contract with $200 Billion Global Consumer Packaged Goods Company for New US Pilot
-
Invesco Ltd: Form 8.3 - International Paper Company; Public dealing disclosure
-
BNP Paribas Primary New Issues: Sammontana No STAB Notice
-
Alliance Trust PLC - Net Asset Value
-
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
-
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries
-
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
-
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
-
Beasley Broadcast Group Announces Expiration of Exchange Offer, Tender Offer and Consent Solicitation and Acceptance of Approximately 98.4% of Outstanding Notes
-
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
